NVCR - Enrollment underway in Novocure's study of Optune with radiation in newly diagnosed brain cancer patients

Novocure ([[NVCR]] +5.0%) has enrolled the first patient in its Phase 3 TRIDENT trial, in newly diagnosed glioblastoma testing the potential survival benefit of initiating Optune concurrent with radiation therapy. Optune is a noninvasive, antimitotic cancer treatment that delivers Tumor Treating Fields using electric fields to disrupt cell division.Currently, Optune with maintenance temozolomide is used to treat adults with glioblastoma, following maximal debulking surgery and completion of radiation therapy.Trident will enroll 950 newly diagnosed GBM patients who, after surgery or biopsy, are candidates for radiation therapy and temozolomide. Patients will continue on Optune for 24 months or until second tumor progression, whichever occurs first.

For further details see:

Enrollment underway in Novocure's study of Optune with radiation in newly diagnosed brain cancer patients